Combination therapy with trimethoprim-sulfamethoxazole and caspofungin in a case of severe pneumocystis pneumonia
Trimethoprim-sulfamethoxazole (TMP-SMX, co-trimoxazole, or bactrim) has been the standard first-line treatment against Pneumocystis jirovecii pneumonia (PCP) for decades. However, adverse effects and cases of treatment failure have led to a search for alternative agents. We present a case of a 50 ye...
Main Authors: | Robin Koshy, Thomas Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | IDCases |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214250918302117 |
Similar Items
-
A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital
by: Hao Li, et al.
Published: (2024-01-01) -
Analysis on Prophylaxis of Pneumocystis Carini Pneumonia by Trimethoprim-Sulfamethoxazole in Patients with Autoimmune Diseases
by: QUE Yongtu, et al.
Published: (2023-01-01) -
Preliminary Study on the Combination Effect of Clindamycin and Low Dose Trimethoprim-Sulfamethoxazole on Severe Pneumocystis Pneumonia After Renal Transplantation
by: Zhun-Yong Gu, et al.
Published: (2022-05-01) -
Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia
by: Wen-Sen Lee
Published: (2017-08-01) -
Severe hypoglycemia during pneumocystis pneumonia treatment associated with trimethoprim–sulfamethoxazole use in a patient on peritoneal dialysis
by: Arata Hibi, et al.
Published: (2017-11-01)